scholarly journals PULMONARY VEIN THROMBOSIS PRESENTING AS MYOCARDIAL INFARCTION

CHEST Journal ◽  
2006 ◽  
Vol 130 (4) ◽  
pp. 344S
Author(s):  
Julio A. Miranda
2012 ◽  
Vol 143 (1) ◽  
pp. e3-e5 ◽  
Author(s):  
Kazuto Ohtaka ◽  
Yasuhiro Hida ◽  
Kichizo Kaga ◽  
Yasuaki Iimura ◽  
Nobuyuki Shiina ◽  
...  

2015 ◽  
Vol 113 (05) ◽  
pp. 1151-1154 ◽  
Author(s):  
Fernando J. Vazquez ◽  
Pilar Paulin ◽  
Paz Rodriguez ◽  
Martin Lubertino ◽  
Esteban Gándara

BMJ ◽  
1972 ◽  
Vol 2 (5811) ◽  
pp. 436-438 ◽  
Author(s):  
A. J. Handley ◽  
P. A. Emerson ◽  
P. R. Fleming

Author(s):  
Imi Faghmous ◽  
Francis Nissen ◽  
Peter Kuebler ◽  
Carlos Flores ◽  
Anisha M Patel ◽  
...  

Aim: Compare thrombotic risk in people with congenital hemophilia A (PwcHA) to the general non-hemophilia A (HA) population. Patients & methods: US claims databases were analyzed to identify PwcHA. Incidence rates of myocardial infarction, pulmonary embolism, ischemic stroke, deep vein thrombosis and device-related thrombosis were compared with a matched cohort without HA. Results: Over 3490 PwcHA were identified and 16,380 individuals matched. PwcHA had a similar incidence of myocardial infarction and pulmonary embolism compared with the non-HA population, but a slightly higher incidence of ischemic stroke and deep vein thrombosis. The incidence of device-related thrombosis was significantly higher in PwcHA. Conclusion: This analysis suggests that PwcHA are not protected against thrombosis, and provides context to evaluate thrombotic risk of HA treatments.


2018 ◽  
Vol 36 (3) ◽  
pp. 76-79
Author(s):  
Avni Merter Keceli ◽  
◽  
Cihan Goktan ◽  
Yavuz Havlucu ◽  
◽  
...  

2008 ◽  
Vol 22 (1) ◽  
pp. 167-168 ◽  
Author(s):  
Emanuele Catena ◽  
Roberto Paino ◽  
Stefano Fieschi ◽  
Alessandro Rinaldo ◽  
Filippo Milazzo ◽  
...  

2014 ◽  
Vol 115 (suppl_1) ◽  
Author(s):  
Hidekazu Takeuchi

Atrial fibrillation can cause ischemic stroke. To prevent atrial fibrillation (AF) is crucial to prevent ischemic stroke. The pulmonary vein has a myocardial layer that can generate spontaneous or triggered action potentials. The myocardial layer is extended from the left atrial myocardium. Pulmonary vein myocardium sleeve is known to be associated with generating and maintaining AF. Pulmonary vein myocardium can be classified into two types. One is short and thin myocardium sleeve, which has no potential to cause atrial fibrillation (AF). And the other is long and thick myocardium sleeve, which has potential to cause AF. The mechanisms of such myocardium sleeve changes are not understood well. Pulmonary vein thrombosis (PVT) is believed to be rare, which was reported as a rare complication of chest surgeries such as lobectomy or lung cancers. But since 2012, I reported seven cases of PVT in elderly patients without such conditions, which suggests that PVT is not uncommon. That is a novel notion. PVT prevents arterial blood flow, which inhibits oxygen and nourishment supply and carbon dioxide excretion. Hypoxia activates hypoxia inducible factors (HIFs), and HIFs can modulate epigenetic changes, reprogramming and ES cells. Undernourishments may activate nuclear respiratory factor-1 (NRF-1) and the aryl hydrocarbon receptor (AhR). PVT can make pulmonary vein acidic states by inhibiting excretion of carbon dioxide and may modulate pulmonary vein myocardium. Under acidic states, pulmonary vein cells such as pulmonary vein myocardium cells may obtain some kinds of multipotency. After obtaining multipotency, the cells may turn into new cells to adapt changed surroundings. The changes of myocardium sleeve may be caused by acidic state conditions and HIFs, AhR and NRF-1, which seemed to modulate pulmonary vein myocardium functions. To clear these, more studies are needed.


1979 ◽  
Author(s):  
H. Arnesen ◽  
Ø. Skjæggestad ◽  
N. Wik

The frequency of deep vein thrombosis (DVT) diagnosed with the 125I-fibrinogen technique in patients with acute myocardial infarction (AMI) has been found to be reduced frcm about 20% without anticoagulation to about 5% with warfarin or small doses of subcutaneous heparin.A somewhat higher incidence of ventricular tachycardia in patients with AMI treated with small doses of subcutaneous heparin has been reported. A possible mechanism might be heparin-induced activation of lipoprotein lipase with consequent increase of plasma free-fatty-acids (FFA), which have been found to be arrhythmogenic in patients with AMI.In the present prospective trial, 99 patients with AMI and a history of less than 12 hours were allocated at random to treatment with subcutaneous heparin 5000 IU twice daily, or warfarin. In a randomized subsample of 21 patients fasting FFA analyses were performed before and 2 hours after the administration of anticoagulants on day 1 and 2.No measurable increase in FFA concentrations was demonstrated in the heparin-treated patients, in spite of a significant influence on the thrombin clotting time.The frequency of ventricular arrhythmias as detected by continous tape recordings was equal in the two treatment groups.It is concluded that subcutaneous heparin 5 000 IU every 12 hours seems to be a safe measures of prophylaxis against venous thromboembolic ccmplications in patients with AMI.


Sign in / Sign up

Export Citation Format

Share Document